Description

Cabometyx is a kinase inhibitor that blocks the action of several enzymes, including VEGFR, RET, ROS1, and KIT, that play a role in cancer cell growth and the development of blood vessels that feed tumors.

The CABOSUN trial showed that Cabometyx slows disease progression in people with advanced kidney cancer not previously treated with targeted therapy. The CELESTIAL trial showed that Cabometyx improved progression-free survival and overall survival in patients with liver cancer that was previously treated with Nexavar (sorafenib).